Krsnaa Diagnostics Limited — Earnings Release 2025

Feb 12, 2025

Date: February 12, 2025 Ref. No.: KDL/SE/130/2024-25

To, To, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Exchange Plaza, Plot No. C-1, Block G, 25th Floor, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (East) Dalal Street, Mumbai- 400001 Mumbai – 400051 Scrip Code: 543328 NSE Symbol: KRSNAA

Dear Sir/Madam,

Sub: Press Release – Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Press Release on the Unaudited (Standalone and Consolidated) Financial Results for the quarter and nine months ended December 31, 2024.

For Krsnaa Diagnostics Limited

SUJOY Digitally signed by SUJOY SUDIPT SUDIPTA BOSE Date: 2025.02.12 A BOSE 18:08:01 +05'30'

Sujoy Sudipta Bose Company Secretary & Compliance Officer Encl: as above

==> picture [595 x 281] intentionally omitted <==

9M FY2025 Press Release

==> picture [76 x 53] intentionally omitted <==

Sustained Growth: 39% EBITDA Surge, 49% PAT Surge YoY & 47% EPS Surge.

Pune, February 12, 2025 : Krsnaa Diagnostics Ltd. (BSE: 543328 | NSE: KRSNAA) is one of India’s fastest growing diagnostic service providers, both in radiology and pathology. The Company today announced the results for the quarter ending December 31[st] , 2024.

Financial Performance Q3 FY2025:

==> picture [530 x 222] intentionally omitted <==

----- Start of picture text -----

Y-o-Y Q-o-Q Y-o-Y
(Rs. Million) Q3FY25 Q3FY24 Q2FY25 9MFY25 9MFY24
Growth Growth Growth
Revenue from
1,745 1,583 10% 1,863 (6%) 5,311 4,534 17%
Operations
Other Income 92 41 46 211 125
Total Income 1,837 1,624 1,909 5,522 4,659
EBITDA [1] 466 378 23% 509 (8%) 1,416 1,020 39%
Margin % 27% 24% 27% 27% 22%
EBIT [1] 316 202 56% 318 (1%) 919 566 62%
Margin % 17% 12% 17% 17% 12%
Profit After Tax 194 130 50% 196 (1%) 569 381 49%
Margin % 11% 8% 11% 11% 8%
Reported
5.88 3.97 5.92 17.26 11.71
`Diluted EPS
----- End of picture text -----

Notes:

1. EBITDA excludes CSR and ESOP and EBIT includes Other Income

Operational Highlights for Q3 FY25 :

• Krsnaa now operates 49 NABL–accredited pathology laboratories in Government hospitals across seven states: Maharashtra, Punjab, Himachal Pradesh, Odisha, Assam, Manipur, and Rajasthan .

• Successfully launched retail operations across four States, Under the brand name “RPL”

• KRSNAA has been honored with the “Leading HR Transformation Award” at the esteemed India HR Summit & Awards 2024

• Krsnaa expanded its presence by establishing 284 additional collection centers across the nation.

Commenting on the results, Mr. Yash Mutha, Joint Managing Director , said:

“We are pleased to report another strong quarter, driven by significant margin improvements, reflecting the success of our operational efficiency initiatives. I am delighted to share that your company has achieved a remarkable profit of Rs. 569 million in 9MFY24, equaling the full-year profit of the previous year. We have successfully launched retail operations in four states, witnessing encouraging traction for our services.

In a major strategic milestone, we have placed a purchase order for machinery under our exclusive partnership with United Imaging and Medikabazaar. This unique arrangement, available only to Krsnaa, allows us to pay 10% upfront while spreading the remaining cost over six years—optimizing cash flow and enabling business expansion

1 | Krsnaa Diagnostics

==> picture [586 x 75] intentionally omitted <==

without additional strain on our balance sheet. This expansion aligns with our mission to provide accessible, affordable, and accurate diagnostics across both urban and rural regions. We remain committed to sustainable, profitable growth by leveraging our core strengths, optimizing cost structures, and investing in high-growth opportunities.

In the first nine months of FY2025, Krsnaa achieved an impressive 17% year-on-year revenue growth, reaching Rs. 5,311 million. Increased awareness of our high-quality service offerings, combined with competitive pricing, has significantly boosted patient volumes and test counts. On the financial front, EBITDA surged 39% YoY to Rs. 1,416 million, with margins improving to 27%. Net profit rose 49% YoY to Rs. 569 million, with net margins at 11%—demonstrating our continued focus on operational efficiency through strategic initiatives. We are confident in maintaining this positive trajectory in the coming quarters.

Looking ahead, our senior management remains fully committed to executing our core growth strategies. We are actively expanding our participation in tenders and strengthening our pipeline for sustained growth. With a clear vision and disciplined execution, we can further solidify our market leadership.”

Commenting on the Business, Ms. Pallavi Bhatevara, Executive Director, said:

“Krsnaa Diagnostics Limited has been a key player in delivering high-quality and affordable diagnostic services, essential for disease diagnosis, management, and prevention. The provision of these services is a fundamental pillar of the healthcare industry.

At Krsnaa, we firmly believe that our employees are the backbone of our success, and we are committed to fostering a work environment that prioritizes their well-being, growth, and professional development. As part of this commitment, we have launched several initiatives aimed at enhancing employee engagement, upskilling, and overall job satisfaction. We have introduced comprehensive training programs designed to equip our workforce with the latest advancements in diagnostic technology, ensuring they remain at the forefront of industry standards.

As we continue to grow, we remain dedicated to investing in our people, ensuring they have the right tools, knowledge, and support to thrive. A well-trained and motivated workforce is key to our mission of providing accessible, affordable, and accurate diagnostics to communities across the country

The recent contract wins highlight the exceptional capabilities of our in-house teams, showcasing their proficiency in navigating the complex bidding process, meeting all requirements, and successfully securing these contracts. As we embark on these projects, Krsnaa Diagnostics is actively expanding its footprint into new geographical regions, laying a strong foundation for sustainable, long-term growth.”

---

2 | Krsnaa Diagnostics

==> picture [586 x 75] intentionally omitted <==

About Krsnaa Diagnostics:

Krsnaa Diagnostics Ltd. is India’s fastest growing differentiated diagnostic services provider, both in Radiology and Pathology. The company started its journey in 2011 with 2 radiology centre and today it is in 15 states and 3 Union Territories with 4,000+ centres across the country. Our mission to be easily accessible and affordable to anyone who seeks best quality diagnosis, and our commitment towards the same is what defines and differentiates us. We deliver clinical excellence through collaborative teleradiology services to enable robust evidence-based treatment for our patients in any corner of the country. With the most advanced technology in place, equipped with an advanced cloud based PACS workflow capable of rapid deployment and easy integration into flexible operational needs, accurate reports are delivered from well-qualified Radiologists and Pathologists from across the globe. We offer exceptional service with prompt turnaround of diagnostic reports, easy access to consultation with our team of diagnostic specialists, and the ability to handle diagnostic report needs. We provide world class healthcare diagnostics services at affordable rates with the approach of “Let’s Do Good...”.

For further information, please contact

Vivek Jain

Head - Investor Relation Krsnaa Diagnostics Ltd.

+91 74107 00645 head.investor@krsnaa.in

Safe Harbour

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Krsnaa Diagnostics Ltd and its subsidiaries/ associates (“Krsnaa Diagnostics”). These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Krsnaa Diagnostics, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.

3 | Krsnaa Diagnostics